% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schmitz:864473,
      author       = {Schmitz, Ann Kristin and Sorg, Rüdiger V. and Stoffels,
                      Gabriele and Grauer, Oliver M. and Galldiks, Norbert and
                      Steiger, Hans-Jakob and Kamp, Marcel A. and Langen,
                      Karl-Josef and Sabel, Michael and Rapp, Marion},
      title        = {{D}iagnostic impact of additional
                      {O}-(2-[18{F}]fluoroethyl)-{L}-tyrosine ( 18 {F}-{FET})
                      {PET} following immunotherapy with dendritic cell
                      vaccination in glioblastoma patients},
      journal      = {British journal of neurosurgery},
      volume       = {35},
      number       = {6},
      issn         = {1360-046X},
      address      = {London [u.a.]},
      publisher    = {Taylor $\&$ Francis},
      reportid     = {FZJ-2019-04251},
      pages        = {736-742},
      year         = {2021},
      abstract     = {Objective: Vaccination therapy using tumour antigen-loaded,
                      autologous dendritic cells (DC) is a promising therapeutic
                      approach alongside standard treatment for glioblastoma
                      (GBM). However, reliable diagnostic criteria regarding
                      therapy monitoring are not established. Here, we analysed
                      the impact of additional 18F-fluoroethyl-tyrosine positron
                      emission tomography (18F-FET PET) imaging following DC
                      vaccination therapy.Methods: We analysed data of GBM
                      patients who received DC vaccination therapy. Following MRI
                      diagnosis of tumour recurrence, additional static and
                      dynamic 18F-FET PET imaging was performed. Vaccination was
                      performed five times by intradermal injections, either
                      weekly between concomitant radio/-chemotherapy and
                      intermittent chemotherapy or after tumour recurrence, before
                      re-radiation therapy. MRI and 18F-FET PET results were
                      compared and correlated with clinical data.Results: Between
                      2003 and 2016, 5 patients were identified who received DC
                      vaccination and 18F-FET PET imaging (1 female/4 males; mean
                      age: 44 ± 14 y). 3/5 patients showed congruent results
                      of tumour progression. In three patients 18F-FET PET
                      indicated treatment related changes, which was in contrast
                      to MRI findings that indicated tumour progression. In these
                      patients 18F-FET PET results could be confirmed by either
                      neuropathological diagnosis or according to the RANO
                      criteriaConclusions: Despite the small patients number our
                      results indicate an additional impact of 18F-FET PET for
                      monitoring outcome following vaccination therapy.},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {31407920},
      UT           = {WOS:000480905300001},
      doi          = {10.1080/02688697.2019.1639615},
      url          = {https://juser.fz-juelich.de/record/864473},
}